IFF outlines a path for Scent recovery anchored in a rebuilt R&D engine and an integrated go-to-market strategy, with Fine Fragrance facing a softer Q3 before a Q4 rebound and Consumer Fragrance expected to normalize to low single-digit growth in 2H 2026. The plan emphasizes higher-value ingredients and sustained R&D investment into 2027 to sustain competitive advantage.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
What are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Management attributes a meaningful part of the Scent recovery to an improvement in R&D capability versus roughly 2.5 years ago—when the R&D pipeline “was not what it should have been” and they were “falling behind,” but is now described as “very strong,” with “a very strong R&D capability,” “great perfumers,” and a “great pipeline of molecules as well as delivery systems” 1. Management also frames this as moving from capability-building toward gap-closure: strengthening strengths, addressing gaps, and progressing toward broader recovery and “an example, the R&D pipeline” turnaround 1.
In Fine Fragrance, management explicitly links performance to navigating Middle East uncertainty: the company expected Fine Fragrance growth “to be down in Fine Fragrance mid-single digits,” but it finished “up slightly positive,” which they credit to “manag[ing] the challenges in the Middle East” 2. For recovery timing, management expects Q3 to be “softer” (with emphasis that this is influenced by difficult year-ago comparisons) and then expects “some recovery as we get to Q4” 2.
For Consumer Fragrance, management points to execution and market share actions: the team has “done a good job on the compounds” and “rebuild[ing] the R&D capability [and] go-to-market approach with customers,” with the stated objective of “trying to drive market share gains” 3. That is reinforced by the company’s view that Consumer Fragrance is in a low single-digit range and had a particularly strong Q2 (high single-digit) that should normalize later 3.
While the question is about “Scent’s recovery” (Fine + Consumer Fragrance), the excerpts show that overall Scent momentum in Q2 was heavily supported by Fragrance Ingredients. Sales were up 8% in Q2, with a key driver being Fragrance Ingredients growth “north of 20%,” helped by the year-ago comparison (comparing to “a down 10% or more in the year ago period”) and by strategically leveraging the synthetics portfolio to capture sales amid macro/supply constraints 2. Management also states an expectation that as conditions settle, this growth “will normalize” and the business will shift “back towards higher value-added ingredients versus traditional synthetics,” which is described as “underway” 32.
Management’s directional growth trajectory for Fine Fragrance in the second half is:
Management’s directional growth trajectory for Consumer Fragrance in the second half is:
Putting the two together:
The excerpts provide both what’s already been built and how management intends to keep innovation capability reinforcing growth and competitiveness into the next years.
Management states that the R&D pipeline is now strong after earlier underperformance (“2.5 years ago…falling behind,” now “today…a very strong R&D capability”), with “leading-edge new Fine Fragrances and Consumer Fragrances” and a “great pipeline of molecules as well as delivery systems” 1. This is the foundation they say supports future evolution of Scent into 2027 1.
Management explicitly links the Ingredients strategy to timing and competitive position: the shift to “higher-value natural products…is underway,” but “will take a little bit more time,” and “as we go into next year and the year after, we believe we’ll have a really strong competitive position” 3. While this sentence is in the context of Fragrance Ingredients, it’s part of the same “Scent” system (compounds, molecules/delivery systems, and ingredient portfolio) and thus is relevant to how R&D supports 2027 competitiveness 3.
Management frames the R&D initiative for Consumer Fragrance as specifically rebuilding both:
Beyond Scent-specific commentary, management describes a broader Remainco innovation thesis: innovation and R&D reinvestment are critical—there’s a described “circle” where investments lead to better growth, which enables margin expansion and continued reinvestment 4. They also quantify R&D intensity at “8% to 9%” of sales and emphasize “critically continue to reinvest” to “making sure we set ourselves apart because it becomes that circle” 4. This supports the idea that R&D funding is planned as a durable strategy component leading through 2027, not a one-off recovery lever 4.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
IFF outlines a Scent recovery anchored in disciplined reinvestment in R&D, a strengthened pipeline, and careful navigation of Middle East volatility, with 2H 2026 expected growth in Fine Fragrance and a normalization to low single digits in Consumer Fragrance. The multi-year R&D plan targets 2027 by advancing molecules, delivery systems, and leading‑edge perfumers to sustain competitive advantage.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF frames Scent's recovery around a rebuilt, stronger R&D pipeline and innovative delivery systems, with Fragrance Ingredients accelerating on higher-value inputs. For H2, Fine Fragrance should see a softer Q3 followed by a stronger Q4, while Consumer Fragrance is expected to grow in the low single digits as R&D and go-to-market efforts support market-share gains—backed by an ongoing 8-9% R&D investment to fuel 2027 growth.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery hinges on a rebuilt R&D engine, stronger go-to-market execution, and resilient Fine Fragrance performance amid regional volatility. In H2, Fine Fragrance is expected to deliver mid-single-digit growth with a soft Q3 and stronger Q4, while Consumer Fragrance normalizes to low single-digit gains; the company reiterates a 2027-focused plan to sustain innovation through heightened R&D investment and a robust molecule and delivery-systems pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Q2 2026 discussion frames a Scent recovery driven by a rebuilt R&D pipeline and stronger Consumer Fragrance execution, with Fine Fragrance set for Q4 recovery. The company emphasizes a longer-term R&D and ingredients strategy to support 2027 and beyond.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF’s Scent recovery is anchored in a rebuilt R&D engine, a stronger fragrance ingredients business, and a strategically paced turnaround for Fine and Consumer Fragrances in the second half of 2026. The discussion also highlights ongoing investments in a broader, more innovative product pipeline and a 2027 plan that relies on go-to-market rebuilds and sustained R&D spend to sustain growth and margin expansion.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines that Scent’s rebound rests on a rebuilt R&D engine, a stronger pipeline, and improved go-to-market execution, with Fine Fragrance soft in Q3 and stronger in Q4, and Consumer Fragrance normalizing to low single-digit growth. The plan ties 2027 readiness to sustained R&D investment and closer customer collaboration, while Fragrance Ingredients normalization poses a near-term headwind before a shift to higher-value natural products strengthens longer-term competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is driven by a rebuilt R&D engine and a stronger end-to-end pipeline, including molecules and delivery systems, alongside leading-edge new fragrances. In H2, Fine Fragrance should see softer Q3 and stronger Q4 amid volatility, while Consumer Fragrance normalizes to low single-digit growth as market share gains persist and go-to-market reforms take hold. The 2027 plan centers on sustaining an 8-9% of sales R&D investment and leveraging innovation to fortify competitive positioning.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a strengthened R&D engine, including a pipeline of distinctive molecules and delivery systems, and a go-to-market revival for Consumer Fragrance. Fine Fragrance benefits from improved execution amid Middle East volatility, with an expected Q3 softness and Q4 rebound, while R&D investment positions the company for stronger competitive positioning through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF maps a resilient Scent recovery driven by Fine Fragrance stabilization, Consumer Fragrance R&D and go-to-market gains, and Fragrance Ingredients momentum, with normalization expected as Scent shifts away from synthetics. For 2H, Fine Fragrance is softer in Q3 and stronger in Q4 (mid-single-digit growth), while Consumer Fragrance should trend to low single digits. The R&D rebuild aims to fortify competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent's recovery hinges on three pillars: Fine Fragrance execution amid Middle East volatility, a Consumer Fragrance strategy built around rebuilding R&D capability and a go-to-market approach to regain market share, and a Fragrance Ingredients tailwind in Q2 that is normalizing as the portfolio shifts toward higher-value ingredients. In H2 2026, Fine Fragrance is expected to maintain mid-single-digit growth while Consumer Fragrance stabilizes at low single-digit, with R&D reinvestment driving a stronger 2027 pipeline.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a science-led recovery for Scent, driven by fragrance ingredients momentum, Fine Fragrance resilience, and a rebuilt Consumer Fragrance GTM with a stronger R&D pipeline. The company expects Q3 softness followed by a stronger Q4 in H2 2026, underpinned by an R&D-led plan for 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery led by a rebuilt R&D engine, with a stronger pipeline and selective management of Middle East volatility. In 2H, Fine Fragrance is expected to hover in mid-single digits (softer in Q3, stronger in Q4) while Consumer Fragrance should normalize to low single digits as go-to-market and R&D revitalization drive market share. The 2027 plan centers on sustained R&D investment and higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Dafinchi